Haemophilus influenzae b polysaccharide-tetanus conjugate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Haemophilus influenzae b polysaccharide-tetanus conjugate
DrugBank Accession Number
DB15876
Background

Not Available

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Conjugate
Synonyms
  • Haemophilus influenzae b polysaccharide - tetanus conjugate
  • Haemophilus influenzae b polysaccharide-tetanus conjugate
  • Haemophilus influenzae type b polysaccharide conjugated to tetanus protein
  • Haemophilus influenzae type b polysaccharide conjugated to the tetanus protein

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HEXAXIMHaemophilus influenzae b polysaccharide-tetanus conjugate (12 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 mcg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injection, suspensionIntramuscularบริษัท ซาโนฟี่ ปาสเตอร์ จำกัด2017-05-31Not applicableThailand flag
INFANRIX - IPV+HIbHaemophilus influenzae b polysaccharide-tetanus conjugate (10 μg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 μg/0.5ml) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (8 μg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 μg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injectionบริษัท แกล็กโซสมิทไคล์น (ประเทศไทย) จำกัด2003-11-01Not applicableThailand flag
INFANRIX HEXAHaemophilus influenzae b polysaccharide-tetanus conjugate (10 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis pertactin antigen (8 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 mcg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injectionบริษัท แกล็กโซสมิทไคล์น (ประเทศไทย) จำกัด2005-05-26Not applicableThailand flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDrug Therapy, Combination / Fever, Chemically Induced / Infants / Vaccines, Pneumococcal1
4CompletedPreventionPertussis1
4CompletedPreventionStreptococcal Infections1
4CompletedPreventionVaccines, Pneumococcal1
4RecruitingPreventionDiphtheria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for suspensionIntramuscular
Injection, suspensionIntramuscular
Injection, powder, for solutionIntramuscular
Injection
SuspensionIntramuscular
Injection, powder, for suspensionIntramuscular
Solution / dropsOral
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 23, 2020 16:20 / Updated on September 24, 2020 11:24